A Johnson and Johnson plant in Brazil (illustration) -
Fotoarena / Sipa USA / SIPA
The United States Medicines Agency (FDA) on Wednesday confirmed the effectiveness of Johnson & Johnson's single-dose vaccine against Covid-19, in documents made public two days before a meeting of its advisory committee to examine its emergency authorization for United States.
The vaccine's efficacy was 85.9% against severe forms of the disease in the United States, and it was also effective against these severe forms at 81.7% in South Africa and 87.6% in Brazil, where variants are widespread.
The FDA has independently studied the results of clinical trials conducted on some 40,000 people in several countries.
“The scans support a favorable safety profile without specific identified safety concerns that could prevent the issuance of an emergency use authorization,” she wrote.
This authorization could take place at the end of the week in the country.
Less effective against moderate forms
All regions of the clinical trial combined, the efficacy of the vaccine 28 days after vaccination was 85.4% against severe forms of the disease.
It was 66.1% against moderate forms of Covid-19.
These data confirm those previously communicated by the pharmaceutical company.
Johnson & Johnson has pledged to ship 100 million doses to the United States by the end of June.
This vaccine is particularly expected because it has two significant advantages in terms of logistics: it can only be administered in a single dose, and it can be stored at refrigerator temperatures, which will considerably facilitate its distribution.
Health
Fewer doses of AstraZeneca in February, Janssen vaccine expected in May instead
Health
With messenger RNA, with viral vector ... Can you choose your anti-Covid vaccine?
World
Covid 19
United States
Anti-covid vaccine
Coronavirus